Cantor Fitzgerald analyst Josh Schimmer initiated coverage of DiaMedica Therapeutics with an Overweight rating and $25 price target. DiaMedica has begun to generate very compelling data for DM199 for treatment of pre-eclampsia, with key opinion leaders indicating a very high unmet need and a very high degree of enthusiasm for this product, the analyst tells investors in a research note. The firm estimates peak sales reaching more than $1B by 2033, but believes this will prove quite conservative.
